By Jason Napodano, CFA, And John Tucker, PhD
Ask a scientist or healthcare portfolio manager what the hot topics are in biotechnology today, and you will likely hear about cancer immunotherapy, stem cells, RNA interference and exon-skipping technologies. One subject they will probably not bring up is the reformulation of 20 year old drugs. Yet, Ireland-based Alkermes plc (ALKS) has grown into a $4 billion company in part by doing exactly that.
As it's impossible to do justice to Alkermes' entire portfolio of products and drug delivery technologies in a single article, we'll focus instead on the company's efforts in the rapidly growing market for long-acting injectable (LAI) drugs for the treatment of schizophrenia. Below, we discuss how...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: